Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation Recurrence Following Electrical Cardioversion

Atrial Fibrillation Clinical Trial

— IERV  

Official title:

Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06399666
• Other study ID #: Dnr 2023-02252-01
• Status: Recruiting
• Start date: October 30, 2023
• Est. completion date: February 28, 2026

Study information

• Verified date: April 2024
• Source: Vrinnevi Hospital
• Contact: Jakob Hytting, MD
• Phone: +461010340807
• Email: jakob.hytting[@]liu.se
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Because of the high recurrence rates following electrical cardioversion and high morbidity in AF patients there is a need to explore prediction models for AF recurrence following ECV. Previous studies have primarily focused on high-sensitivity CRP (hsCRP), CRP, and IL-6, while other inflammatory indexes and gene scores might hold greater value. This prospective cohort study is planning to include 205 patients with persistent atrial fibrillation, planned for electrical cardioversion, and >18 years at two medium-sized hospitals in Sweden. Blood samples will be collected prior to electrical cardioversion and at 7-, 30-, 90-, and 180-days follow-up. Atrial fibrillation recurrence will be evaluated at follow-up or upon patient request and diagnosed with 12-lead ECG.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 205
• Est. completion date: February 28, 2026
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• persistent atrial fibrillation (ICD-10 I48.1), age over 18 years

Exclusion Criteria:

• autoimmune diseases, inflammatory diseases, acute or chronic liver dysfunction, ongoing infectious diseases, thyroid disorders, or any other conditions known to impact inflammatory activity (including medication use and hematological diseases)

Related Conditions & MeSH terms

• Atrial Fibrillation
• Genetic Predisposition to Disease
• Inflammation

Intervention

Other:
• Blood sampling
Blood sampling

Locations

Country	Name	City	State
Sweden	Medical department	Jönköping	Småland
Sweden	Cardiology Clinic	Norrköping	Östergötland

Sponsors (2)

Lead Sponsor	Collaborator
Vrinnevi Hospital	Ryhov Hospital

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence in atrial fibrillation		During follow-up (post ECV, day 7 - 180)